A5052070790- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
- COVID-19 Clinical Research Studies
- Immunotherapy and Immune Responses
- Bacillus and Francisella bacterial research
University of Hong Kong
2021-2022
By vaccinating SARS-CoV-2 naïve individuals who have already received two doses of COVID-19 vaccines, we aimed to investigate whether a heterologous prime-boost strategy, using vaccines different platforms as the booster dose, can enhance immune response against virus variants. Participants were assigned into four groups, each receiving combination vaccinations: BNT162b2 followed by one dose (B-B-B); Combination (first dose) and CoronaVac (second (B-C-B); (C-C-C); (C-C-B). The neutralizing...
Vaccinating recovered patients previously infected by COVID-19 with mRNA vaccines to boost their immune response against wild-type viruses (WT), we aimed investigate whether vaccine platform and time of vaccination affect immunogenicity the SARS-CoV-2 WT Delta variant (DV). Convalescent were recruited received one booster dose BNT162b2 (PC-B) or CoronaVac (PC-C) vaccines, while naïve subjects two doses (CN-B) (CN-C) vaccines. The neutralizing antibody in sera DV was determined live virus...